These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 36179388)

  • 1. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
    Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
    Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
    Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
    Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
    Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
    Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic breast cancer subtypes and central nervous system metastases.
    Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
    Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
    Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
    Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and systemic therapy in breast cancer patients with central nervous system metastases.
    Wellerdieck NEA; Wessels P; Los M; Sonke GS; Tromp E; Brandsma D
    Breast Cancer Res Treat; 2022 Jul; 194(2):365-384. PubMed ID: 35680734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
    Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
    J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer subtypes and survival in patients with brain metastases.
    Nam BH; Kim SY; Han HS; Kwon Y; Lee KS; Kim TH; Ro J
    Breast Cancer Res; 2008; 10(1):R20. PubMed ID: 18307763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and survival outcomes in patients with brain metastases from breast cancer.
    Minisini AM; Moroso S; Gerratana L; Giangreco M; Iacono D; Poletto E; Guardascione M; Fontanella C; Fasola G; Puglisi F
    Clin Exp Metastasis; 2013 Dec; 30(8):951-6. PubMed ID: 23775210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between body mass index and immunohistochemical subtypes in breast cancer.
    Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
    Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
    Laakmann E; Witzel I; Fasching PA; Rezai M; Schem C; Solbach C; Tesch H; Klare P; Schneeweiss A; Salat C; Zahm DM; Blohmer JU; Ingold-Heppner B; Huober J; Hanusch C; Jackisch C; Reinisch M; Untch M; von Minckwitz G; Nekljudova V; Müller V; Loibl S
    Breast Cancer Res; 2019 May; 21(1):60. PubMed ID: 31077239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype.
    Kim HK; Lee HS; Heo MH; Kim JY; Ahn JS; Im YH; Lee JI; Park YH
    Clin Breast Cancer; 2021 Aug; 21(4):e402-e414. PubMed ID: 33526378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.